超保护性通气减少接受静脉-静脉体外膜氧合治疗的严重急性呼吸窘迫综合征患者的生物创伤
该随机临床试验在单中心纳入16例接受静脉-静脉体外膜氧合(VV-ECMO)的严重急性呼吸窘迫综合征患者,在ECMO启动后转为双水平气道正压模式并随机接受三种实验性通气设置。ECMO启动后的超保护性通气设置与显著降低的血浆sRAGE、白细胞介素-6和单核细胞趋化蛋白-1浓度相关;各ECMO在机实验步骤间血浆sRAGE和细胞因子相当,但支气管肺泡灌洗液sRAGE最低值出现在最小驱动压时。作者认为该通气策略显著限制了肺部生物创伤,可能因此减少呼吸机相关性肺损伤,但ECMO启动后的最佳超保护性通气策略仍未确定,需进一步研究。
要点
- 严重ARDS患者启动VV-ECMO后转为超保护性通气,与显著降低的血浆sRAGE、IL-6和MCP-1浓度相关。
- 各ECMO在机实验步骤间血浆sRAGE和细胞因子相当,但支气管肺泡灌洗液sRAGE最低值出现在最小驱动压时。
- 超保护性通气组合了显著更低的气道平台压、潮气量和驱动压。
- 作者认为该通气策略显著限制了肺部生物创伤,可能因此减少呼吸机相关性肺损伤。
- 作者指出ECMO启动后的最佳超保护性通气策略仍未确定,需进一步研究。
适用人群与场景
- 严重急性呼吸窘迫综合征患者,接受静脉-静脉体外膜氧合(VV-ECMO)支持。
- 纳入16例患者,机械通气7天(1-11天)后接受ECMO。
处置流程与药物剂量
- 启动ECMO后转为双水平气道正压模式:高压24 cm H2O持续1秒,低压12 cm H2O持续2秒,共24小时。
- 随后随机接受三种实验步骤:1)高压24 cm H2O、低压20 cm H2O(极高呼气末正压-极低驱动压);2)高压24 cm H2O、低压5 cm H2O(低呼气末正压-高驱动压);3)高压17 cm H2O、低压5 cm H2O(低呼气末正压-低驱动压)。
- 在ECMO前及每个步骤12小时后采样血浆和支气管肺泡灌洗液可溶性晚期糖基化终末产物受体、血浆白细胞介素-6和单核细胞趋化蛋白-1。
研究设计与关键结果
- 随机临床试验,单中心,为期九个月,纳入16例接受VV-ECMO的严重ARDS患者。
- ECMO启动后的超保护性通气设置与显著降低的血浆sRAGE、白细胞介素-6和单核细胞趋化蛋白-1浓度相关。
- 各ECMO在机实验步骤间血浆sRAGE和细胞因子相当,但支气管肺泡灌洗液sRAGE最低值出现在最小驱动压时。
- 超保护性通气组合了显著更低的气道平台压、潮气量和驱动压。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为超保护性通气策略显著限制了肺部生物创伤,可能因此减少呼吸机相关性肺损伤。
- 作者指出ECMO启动后的最佳超保护性通气策略仍未确定,需进一步研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Ventilator settings for patients with severe acute respiratory distress syndrome supported by venovenous extracorporeal membrane oxygenation are currently set arbitrarily. The impact on serum and pulmonary biotrauma markers of the transition to ultra-protective ventilation settings following extracorporeal membrane oxygenation implantation, and different mechanical ventilation strategies while on extracorporeal membrane oxygenation were investigated.
DESIGN: Randomized clinical trial.
SETTINGS: Nine-month monocentric study.
PATIENTS: Severe acute respiratory distress syndrome patients on venovenous extracorporeal membrane oxygenation.
INTERVENTIONS: After starting extracorporeal membrane oxygenation, patients were switched to the bi-level positive airway pressure mode with 1 second of 24 cm H2O high pressure and 2 seconds of 12 cm H2O low pressure for 24 hours. A computer-generated allocation sequence randomized patients to receive each of the following three experimental steps: 1) high pressure 24 cm H2O and low pressure 20 cm H2O (very high positive end-expiratory pressure-very low driving pressure); 2) high pressure 24 cm H2O and low pressure 5 cm H2O (low positive end-expiratory pressure-high driving pressure); and 3) high pressure 17 cm H2O and low pressure 5 cm H2O (low positive end-expiratory pressure-low driving pressure). Plasma and bronchoalveolar lavage soluble receptor for advanced glycation end-products, plasma interleukin-6, and monocyte chemotactic protein-1 were sampled preextracorporeal membrane oxygenation and after 12 hours at each step.
MEASUREMENTS AND MAIN RESULTS: Sixteen patients on ECMO after 7 days (1-11 d) of mechanical ventilation were included. "Ultra-protective" mechanical ventilation settings following ECMO initiation were associated with significantly lower plasma sRAGE, interleukin-6, and monocyte chemotactic protein-1 concentrations. Plasma sRAGE and cytokines were comparable within each on-ECMO experimental step, but the lowest bronchoalveolar lavage sRAGE levels were obtained at minimal driving pressure.
CONCLUSIONS: ECMO allows ultra- protective ventilation, which combines significantly lower plateau pressure, tidalvolume, and driving pressure. This ventilation strategy significantly limited pulmonary biotrauma, which couldtherefore decrease ventilator-induced lung injury. However, the optimal ultra-protective ventilation strategy once ECMO is initiated remains undetermined and warrants further investigations. (Crit Care Med 2019; 47:1505-1512).
参考来源
- Rozencwajg S, Guihot A, Franchineau G, et al. Ultra-Protective Ventilation Reduces Biotrauma in Patients on Venovenous Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome. Crit Care Med. 2019. PMID: 31385880. doi:10.1097/CCM.0000000000003894
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。